Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended March 31, 2026 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share Total Number of Shares
Purchased as Part of
Publicly Announced Plans or
Programs
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
January 1 - January 31
3,283,324 $108.62 3,283,324 $6,964
February 1 - February 28
2,254,286 $119.10 2,254,286 $6,696
March 1 - March 31
2,121,980 $117.17 2,121,980 $6,447
Total 7,659,590 $114.07 7,659,590
(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in January 2025 to purchase up to $10 billion of Merck’s common stock for its treasury.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.